Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry.

Franck F RahaghiRichard MonkViswanathan RamakrishnanTatsiana BeikoCharlie B Strange

Published in: International journal of chronic obstructive pulmonary disease (2020)

There is a survival benefit from augmentation therapy in AATD between FEV1 values in the 10-60% predicted range. Screening and treatment of AATD patients should therefore not be limited by the severity of illness as defined by FEV1.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
soft tissue
free survival
stem cells
patient reported outcomes